We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) and Vir Biotechnology have filed for Emergency Use Authorization (EUA) for their SARS-CoV-2 monoclonal antibody ahead of schedule, having recently stopped their phase 3 trial after seeing significantly positive results. Read More
The Pfizer/BioNTech COVID-19 vaccine is seeing progress on multiple fronts, including a newly launched study in children as young as six months old, a billion-dose a year manufacturing facility that will come on stream in Germany next month and less onerous storage temperatures expected soon in the EU. Read More
A group of academics, policy experts and nonprofits has penned a letter to HHS and the National Institutes of Health (NIH) urging the government to draw up provisions that improve global access to Moderna’s COVID-19 vaccine as part of any patent-licensing agreement for the drugmaker. Read More
As Novavax gears up to file for authorizations for its two-dose COVID-19 vaccine, the U.S. drugmaker has been working to significantly expand its manufacturing capabilities in Europe and other parts of the globe and believes it can supply well over 100 million doses a month by the fall. Read More
Researchers from Oxford University and Imperial College London started a separate trial in September 2020 to evaluate inhaled COVID-19 vaccine candidates. Read More
In his first presidential news conference yesterday, President Biden set a new goal of 200 million COVID-19 vaccinations by his 100th day in office — doubling his initial goal. Read More
AstraZeneca (AZ) responded to National Institutes of Health (NIH) concerns over its interim vaccine trial data by releasing its primary analysis results yesterday, but the embattled company’s two-dose shot faces intense scrutiny, with the European Medicines Agency (EMA) holding an expert meeting on March 29 to review possible links to blood clots. Read More
The test, which has also been cleared in Europe, is run on the company’s immunoassay analyzers, including its DxI 800 system, which can process up to 4,800 samples daily. Read More
A new report analyzing drug research and development (R&D) during the pandemic found that while cancer drugs have remained industry’s top focus, anti-infective drugs saw the biggest increase of all therapies due to the monumental efforts to combat the COVID-19 crisis. Read More
Johnson & Johnson (J&J) said it expects to deliver 20 million doses of its COVID-19 vaccine for the U.S. by the end of March, as officials nationwide continued to complain of severely limited supplies of the single-shot vaccine. Read More
As Europe continues to face challenges and setbacks in its COVID-19 vaccination efforts, the European Commission (EC) has proposed new criteria for vaccine export authorizations to conserve its supplies. Read More
RSS
